Literature DB >> 6409137

Clinical correlates of in vitro drug sensitivities of ovarian cancer cells.

L Morasca, E Erba, M Vaghi, C Ghelardoni, C Mangioni, C Sessa, F Landoni, S Garattini.   

Abstract

Of 89 samples of cancer cells from ovarian cancer patients primary cultures representative of the cancer cell population could be established in 17. The clinical response to polychemotherapy was studied in relation to the inhibition of thymidine uptake by the cultured cells. Cultures of each patient's tumour were exposed to concentrations of the drugs the patients had been given for long enough to reproduce the area under the curve (AUC) of the plasma levels resulting from in vivo dosage. Full agreement was observed between the degree of thymidine uptake inhibition induced by at least one of the drugs administered to the cultured cells and the degree of clinical response. This approach may prove useful in pharmacological studies as a means of obtaining ovarian cancer cell populations representative of human tumours, even though the number of tumours that can be successfully evaluated in vitro is still too small to serve as a sound basis for prediction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6409137      PMCID: PMC2011415          DOI: 10.1038/bjc.1983.157

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Time dependent cytotoxicity of adriamycin and daunomycin in primary cultures of normal and neoplastic mammary glands.

Authors:  L Morasca; E G Fogar-Ottaviano; S Garattini
Journal:  Eur J Cancer       Date:  1976-02       Impact factor: 9.162

Review 2.  Treatment of ovarian carcinoma: possibilities for progress.

Authors:  C M Bagley; R C Young; G P Canellos; V T DeVita
Journal:  N Engl J Med       Date:  1972-10-26       Impact factor: 91.245

3.  Cytotoxic effect in vitro and tumour volume reduction in vivo induced by chemotherapeutic agents.

Authors:  L Morasca; G Balconi; E Erba; P Lelieveld; L M Van Putten
Journal:  Eur J Cancer       Date:  1974-10       Impact factor: 9.162

4.  The effect of phenobarbital or 2-diethylaminoethyl-2,2-diphenylvalerate on the activation of cyclophosphamide in vivo.

Authors:  R B Field; M Gang; I Kline; J M Venditti; V S Waravdekar
Journal:  J Pharmacol Exp Ther       Date:  1972-02       Impact factor: 4.030

5.  Variable oral absorption of hexamethylmelamine in man.

Authors:  M D'Incalci; G Bolis; C Mangioni; L Morasca; S Garattini
Journal:  Cancer Treat Rep       Date:  1978-12

6.  Effects on in vitro tumor growth of macrophages isolated from human ascitic ovarian tumors.

Authors:  A Mantovani; G Peri; N Polentarutti; G Bolis; C Mangioni; F Spreafico
Journal:  Int J Cancer       Date:  1979-02       Impact factor: 7.396

7.  Kinetics of cis-dichlorodiammineplatinum.

Authors:  P E Gormley; J M Bull; A F LeRoy; R Cysyk
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

8.  The effect of phenobarbital on cyclophosphamide antitumor activity.

Authors:  D S Alberts; T van Daalen Wetters
Journal:  Cancer Res       Date:  1976-08       Impact factor: 12.701

9.  Pharmacokinetics of fluorouracil in humans.

Authors:  W E MacMillan; W H Wolberg; P G Welling
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

10.  Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.

Authors:  R S Benjamin; C E Riggs; N R Bachur
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

View more
  1 in total

Review 1.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.